Last updated: August 22, 2026
Clomipramine hydrochloride is a mature, multisource generic tricyclic antidepressant used primarily for obsessive-compulsive disorder (OCD). Its U.S. market has low regulatory barriers, no meaningful remaining exclusivity, and limited manufacturer pricing power. Commercial value is concentrated in steady chronic prescriptions rather than premium pricing or innovation-led growth. The main risks are generic substitution, low reimbursement, supply concentration, and competition from SSRIs and behavioral therapy.
What is the current FDA regulatory status of clomipramine hydrochloride?
Clomipramine hydrochloride is FDA-approved in oral capsule strengths of 25 mg, 50 mg, and 75 mg for the treatment of OCD in adults and pediatric patients age 10 and older. The original U.S. reference product was Anafranil, developed by Ciba-Geigy and later associated with Novartis. The original New Drug Application is NDA 019839. [1]
| Regulatory item |
Status |
| Active ingredient |
Clomipramine hydrochloride |
| Drug class |
Tricyclic antidepressant |
| Primary FDA indication |
Obsessive-compulsive disorder |
| Dosage form |
Oral capsule |
| U.S. strengths |
25 mg, 50 mg, 75 mg |
| Original brand |
Anafranil |
| Original NDA |
NDA 019839 |
| FDA approval era |
1989 |
| Current market |
Generic and branded-generic |
| Controlled-substance status |
Not scheduled under the federal Controlled Substances Act |
| Biosimilar pathway |
Not applicable |
FDA labeling identifies clomipramine as a serotonin and norepinephrine reuptake inhibitor with anticholinergic, antihistaminic, and cardiovascular effects. Its adverse-effect profile limits broad substitution for newer antidepressants, particularly in patients at risk of arrhythmia, seizures, overdose, or anticholinergic complications. [1]
When does clomipramine hydrochloride lose exclusivity?
Clomipramine hydrochloride lost meaningful U.S. market exclusivity decades ago. The original product was approved in 1989, and generic approvals followed after the expiration or resolution of the relevant patent and regulatory exclusivity rights.
The drug has no current small-molecule exclusivity comparable to a new chemical entity, pediatric exclusivity, or first-to-file generic advantage. A new applicant therefore competes in a conventional abbreviated new drug application market rather than a protected launch window.
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
Expired or not commercially relevant |
| First generic exclusivity |
Expired |
| Patent-based exclusivity |
No material current U.S. exclusivity identified |
| Regulatory protection for the active ingredient |
None of commercial significance |
The practical implication is that a generic entrant cannot rely on six months of protected market access or on a remaining Orange Book patent barrier. Entry economics depend on approval timing, manufacturing cost, supply reliability, wholesaler access, and reimbursement contracts.
What patents protect clomipramine hydrochloride?
The core clomipramine hydrochloride molecule is long off-patent. The public FDA Orange Book framework does not indicate a commercially meaningful active patent estate protecting the basic capsule product. [2]
Formulation patents
The U.S. market has not developed a major extended-release or complex-delivery platform around clomipramine hydrochloride. Conventional immediate-release capsules dominate the approved product category.
Potential formulation claims could cover:
- Modified-release capsules
- Taste-masked oral products
- Liquid formulations
- Abuse-deterrent systems
- Combination products
- Pediatric dosage forms
- Pharmacokinetic optimization
No such formulation category has created a significant U.S. market exclusivity position comparable with extended-release reformulations of other antidepressants.
Method-of-use patents
The principal FDA-approved use is OCD. Any historic method-of-use protection associated with treatment of OCD is expired or commercially immaterial. Potential new claims involving treatment-resistant OCD, augmentation, pediatric dosing, or biomarker-selected patients would face written-description, obviousness, enablement, and clinical utility challenges.
A new method-of-use patent would not automatically prevent generic prescribing for OCD because generic manufacturers could seek a label that omits the patented use, subject to the scope of the claims and applicable inducement analysis.
How many patents cover clomipramine hydrochloride?
The commercially relevant number of active U.S. patents covering the standard clomipramine hydrochloride capsule is effectively zero based on the current FDA product and Orange Book framework. [2]
This does not mean that no historical patent documents ever mentioned clomipramine. It means that the standard product has no visible patent moat capable of supporting premium pricing or delaying ordinary ANDA competition.
| Patent-estate factor |
Assessment |
| Core composition patent |
Expired |
| Standard capsule patent |
No material active barrier identified |
| Drug-delivery patent |
No major commercial barrier identified |
| Method-of-use protection |
Expired or commercially limited |
| Patent litigation leverage |
Low |
| Freedom-to-operate risk for ordinary capsules |
Low, subject to claim-level review |
| Strategic value of new formulation patents |
Potentially meaningful but unproven |
What is the Orange Book status of clomipramine hydrochloride?
Clomipramine hydrochloride is an established generic product with FDA-approved ANDAs and an old reference product. The Orange Book is relevant for confirming therapeutic equivalence and any listed patents or exclusivity. It does not provide a current commercial barrier comparable with protected branded products. [2]
A standard generic applicant would typically pursue:
- An ANDA referencing the listed drug.
- Bioequivalence to the reference product.
- Capsule strengths matching the approved product.
- A Paragraph IV certification only if an unexpired listed patent were present.
- Labeling consistent with the permitted use of the reference product.
Because the central patents are expired, Paragraph IV litigation is not a defining feature of the current clomipramine market.
Which companies are challenging clomipramine hydrochloride exclusivity?
No active, market-defining Paragraph IV campaign is associated with clomipramine hydrochloride. The competitive challenge occurred historically through ordinary generic approvals rather than through a current branded-patent dispute.
The U.S. market has included generic suppliers and distributors such as:
- Teva Pharmaceuticals
- Rising Pharmaceuticals
- Mylan, now part of Viatris
- ANI Pharmaceuticals and other specialty-generic suppliers
- Private-label and wholesaler-distributed manufacturers
Manufacturer participation can change as companies discontinue low-volume products, transfer ANDAs, or exit low-margin generic categories. FDA Drugs@FDA and the Orange Book remain the authoritative sources for current approval holders and therapeutic-equivalence information. [2, 3]
What patent litigation affects clomipramine hydrochloride?
No significant current U.S. patent litigation appears to affect standard clomipramine hydrochloride capsules. The product’s litigation exposure is low because:
- The original composition patent estate is old.
- Generic entry has already occurred.
- No premium formulation dominates the market.
- The reference product does not have a high-value remaining exclusivity position.
- The drug generates insufficient branded revenue to justify extensive lifecycle litigation.
Litigation risk could increase if a company introduced a new delivery technology or pursued a narrow indication with a patent-protected label. That scenario would concern the new formulation or use, not the conventional clomipramine capsule.
What generic entry risks exist for clomipramine hydrochloride?
Generic entry risk is already realized rather than prospective. The market operates as a mature generic category.
Commercial risks for manufacturers
The main risks are:
- Low average selling prices
- Small patient population relative to major antidepressants
- Pharmacy substitution
- Contracting pressure from wholesalers and pharmacy benefit managers
- Product discontinuation if volumes do not support minimum batch sizes
- Active pharmaceutical ingredient supply interruptions
- Limited ability to pass through manufacturing inflation
- Therapeutic substitution to SSRIs
Regulatory and manufacturing barriers
The technical manufacturing barrier is moderate. Clomipramine hydrochloride is a conventional small-molecule solid oral product, so it does not require sterile filling, biologic comparability, or complex-device development.
Manufacturers still must control:
- Assay and impurity profile
- Capsule content uniformity
- Dissolution
- Stability
- Bioequivalence
- Packaging and moisture protection
- Cross-contamination controls
- Pharmacovigilance for psychiatric adverse events
The product’s toxicology profile raises quality and labeling stakes. Tricyclic antidepressants can be dangerous in overdose, and FDA labeling includes boxed warnings concerning suicidality in pediatric, adolescent, and young adult patients treated with antidepressants. [1]
How does clomipramine compare with competing OCD drugs?
Clomipramine has strong historical efficacy in OCD but competes against better-tolerated SSRIs and non-drug treatment. The American Psychiatric Association and other clinical guidelines generally recognize SSRIs and clomipramine as effective pharmacologic options, while exposure and response prevention remains a central behavioral intervention. [4]
| Product or treatment |
Commercial position versus clomipramine |
| Fluoxetine |
Broad generic availability and larger prescriber base |
| Fluvoxamine |
FDA-approved for OCD and often used when serotonin-focused treatment is preferred |
| Sertraline |
Broad primary-care use and strong generic competition |
| Paroxetine |
Generic, but adverse-effect concerns limit some use |
| Escitalopram |
Common off-label OCD option with strong antidepressant demand |
| Clomipramine |
Often reserved for inadequate SSRI response or selected patients |
| Exposure and response prevention |
Important non-drug substitute and adjunct |
Clomipramine’s competitive advantage is its established OCD efficacy and specialist familiarity. Its disadvantages include sedation, dry mouth, constipation, weight gain, sexual dysfunction, orthostatic hypotension, cardiac-conduction concerns, and greater overdose toxicity than many SSRIs. [1, 4]
What is the financial trajectory of clomipramine hydrochloride?
The financial trajectory is characteristic of a mature generic:
- Brand-stage revenue and pricing declined after patent expiry.
- Multiple generic entrants reduced price and increased substitution.
- Revenue shifted from innovation economics to manufacturing economics.
- Current value depends on prescription volume, supply continuity, and portfolio fit.
- Long-term growth is likely limited unless a new formulation, indication, or distribution strategy changes the category.
Public companies generally do not report clomipramine revenue as a standalone line item. It is usually grouped within broader generic pharmaceutical revenue. A precise global market size, manufacturer share, or product-level revenue figure cannot be derived from public annual reports alone.
Revenue exposure
Clomipramine is unlikely to be material to the consolidated revenue of large diversified generic companies. Its commercial importance is greater for:
- Small specialty-generic companies
- Contract manufacturers
- Niche distributors
- Pharmacies managing intermittent supply
- Companies with a portfolio of psychiatric medicines
The product can still generate recurring cash flow because OCD treatment is chronic and discontinuation can be difficult. That recurring demand is offset by low unit prices and competition from multiple therapeutic alternatives.
Pricing dynamics
Pricing is shaped by:
- Number of approved suppliers
- Wholesaler inventory
- Pharmacy benefit-manager contracts
- Dosage strength
- Shortages or discontinuations
- Retail versus mail-order dispensing
- Medicaid and Medicare reimbursement
- Manufacturer channel strategy
The highest-margin opportunity is generally not the standard capsule. It would be a differentiated product such as an extended-release formulation, pediatric formulation, liquid product, or clinically supported combination approach. Each would require new clinical, regulatory, and intellectual-property investment.
What geographic markets offer commercial opportunity?
The United States is a mature generic market with limited patent-based upside. Commercial opportunities are more likely to arise from supply reliability, geographic distribution, and local regulatory positioning than from exclusivity.
| Region |
Market characteristics |
| United States |
Mature generic market; no core patent moat |
| European Union |
Generic competition; national reimbursement and pricing controls |
| Japan |
Regulatory and reimbursement requirements; established antidepressant alternatives |
| Latin America |
Variable brand loyalty and generic penetration |
| Asia-Pacific |
Potential volume growth but strong local price competition |
| Emerging markets |
Access-driven demand; distributor and registration execution are critical |
International patent and regulatory status must be assessed country by country. U.S. patent expiry does not establish freedom to operate in Europe, Japan, China, India, or Latin America.
How strong is the clomipramine hydrochloride patent estate?
The patent estate is weak for the conventional product and has no evident ability to support premium pricing. Its strategic value is mainly defensive: a company could seek narrowly drafted patents for a novel formulation, manufacturing process, dosing regimen, or patient-selection method.
| Dimension |
Strength |
| Core molecule |
Very weak |
| Standard capsule |
Weak |
| New formulation opportunity |
Potentially moderate |
| Method-of-use opportunity |
Narrow and uncertain |
| Manufacturing know-how |
Moderate operational value |
| Regulatory exclusivity |
None of commercial significance |
| Litigation leverage |
Low |
| Generic-entry protection |
Minimal |
Key Takeaways
- Clomipramine hydrochloride is an old, FDA-approved generic drug used mainly for OCD.
- The original Anafranil exclusivity period ended decades ago.
- No material active U.S. patent barrier protects the conventional capsule product.
- Paragraph IV challenges and current patent litigation are not major market drivers.
- The product has no biosimilar risk because it is a small-molecule drug, not a biologic.
- Revenue is recurring but modest, fragmented, and rarely disclosed separately by manufacturers.
- Competition from fluoxetine, fluvoxamine, sertraline, paroxetine, other SSRIs, and exposure-response prevention limits growth.
- Manufacturing and supply reliability matter more than patent exclusivity.
- A differentiated formulation or new indication would be required to create meaningful pricing power.
FAQs
Is clomipramine hydrochloride still commercially viable?
Yes, as a niche generic product. Its viability depends on stable OCD demand, manufacturing cost, and supplier participation rather than brand pricing or patent protection.
Is Anafranil still protected by patents?
No material U.S. patent protection for the conventional Anafranil capsule appears to remain commercially relevant. The brand competes in a market dominated by generic substitution.
Can a company obtain new patents on clomipramine hydrochloride?
Yes. A company could pursue patents covering a novel formulation, delivery system, dosing regimen, manufacturing process, or narrow method of use. The claims would need to provide a genuine technical or clinical distinction over the known product.
Does clomipramine hydrochloride have biosimilar competition?
No. Biosimilars apply to biological products. Clomipramine hydrochloride is a chemically synthesized small-molecule drug and is subject to the ANDA generic pathway.
What would cause clomipramine prices to increase?
The most likely causes would be supplier exits, manufacturing disruption, API shortages, regulatory recalls, or a sharp reduction in the number of approved manufacturers. A patent-based price increase is unlikely for the standard product.
References
-
U.S. Food and Drug Administration. (2017). Anafranil (clomipramine hydrochloride) capsule prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019839s074lbl.pdf
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
American Psychiatric Association. (2007). Practice guideline for the treatment of patients with obsessive-compulsive disorder. American Psychiatric Association.
